<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 14, Issue 03 , 2022 </Volume-Issue>
      <Season>July-September </Season>
      <ArticleType>P'Ceutical Chemistry</ArticleType>
      <ArticleTitle>Synthetic strategy of 2-thioxo-4-thiazolidinone with core chemistry and biological importance</ArticleTitle>
          <FirstName>Pooja A.</FirstName>
      <DOI> 10.56933/Pharmaspire.2022.14212</DOI>
      <Abstract>Due to the vast range of biological actions that rhodanine and its derivatives exhibit, they are recognized as privileged structures in pharmacological research. However, the rhodanine skeleton synthesis process has certain limitations. However, the rhodanine ring’s reactivity enabled the creation of various arylidenes at position 5 and carboxylic acids at position 3, respectively. The principal pathways of heterocycle alteration are determined by the most reactive sites in 4-thiazolidinone, which are 3 and 5. In a review paper, the chemistry of 4-thiazolidinones was discussed, in particular the rhodanine ring and several methods for its reactions, including ring modification. The study deals with thioureas and thioglycolic acid react in a single step, catalyzed by protic acid, resulting in the direct preparation of N-aryl rhodanines as well as the rhodanine skeleton, offering a novel method for the synthesis of rhodanine and its derivatives. The presented approach is simple, effective, atom-efficient, and practical in high yields.</Abstract>
      <Keywords>4-Thiazolidinones, Heterocycle, Methylene carbon, Rhodanine, SN2 type, Synthesis, Thiazolidone, Thioglycolic acid, Thiourea</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14325&amp;title=Synthetic strategy of 2-thioxo-4-thiazolidinone with core chemistry and biological importance</Abstract>
        <References>1. Kaminskyy D, Kryshchyshyn A, Lesyk R. Recent developments with rhodanine as a scaffold for drug discovery. Expert Opin Drug Discov 2017;12:1233-52.&#13;
2. Toumi A, Boudriga S, Hamden K, Sobeh M, Cheurfa M, Askri M, et al. Synthesis, antidiabetic activity and molecular docking study of rhodanine-substitued spirooxindole pyrrolidine derivatives as novel and;aacute;-amylase inhibitors. Bioorg Chem 2021;106:104507.&#13;
3. Tejchman W, Korona-Glowniak I, Kwietniewski L, ?es?awska E, Nitek W, Suder P, et al. Antibacterial properties of 5-substituted derivatives of rhodanine-3- carboxyalkyl acids. Part II. Saudi Pharm J 2020;28:414-26.&#13;
4. Kumar BR, Basu P, Adhikary L, Nanjan MJ. Efficient conversion of N-terminal of L-tyrosine, DL-phenyl alanine, and glycine to substituted 2-thioxo-thiazolidine- 4-ones: A stereospecific synthesis. Synth Commun 2012;42:3089-96.&#13;
5. Tintori C, Iovenitti G, Ceresola ER, Ferrarese R, Zamperini C, Brai A, et al. Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides. PloS One. 2018;13:e0198478.&#13;
6. Rajamaki S, Innitzer A, Falciani C, Tintori C, Christ F, Witvrouw M, et al. Exploration of novel thiobarbituric acid-, rhodanine-and thiohydantoin-based HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2009;19:3615-8.&#13;
7. Chauhan K, Sharma M, Saxena J, Singh SV, Trivedi P, Srivastava K, et al. Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents. Eur J Med Chem 2013;62:693-704.&#13;
8. and;Aacute;lvarez-Ginarte Y, Moreno-Castillo E, Montero-Cabrera LA, Bencomo-Martand;iacute;nez A, Gonzand;aacute;lez-Alemand;aacute;n R, Leclerc F, editors. Integrative Model of Rhodanine Derivatives as Tau Aggregation Inhibitors in Alzheimer’s disease. Bioinfomics2019 ix International Meeting on Bioinformatics and Omics; 2019.&#13;
9. Azizmohammadi M, Khoobi M, Ramazani A, Emami S, Zarrin A, Firuzi O, et al. 2H-chromene derivatives bearing thiazolidine-2, 4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 2013;59:15-22.&#13;
10. Khodair AI, Awad MK, Gesson JP, Elshaier YA. New N-ribosides and N-mannosides of rhodanine derivatives with anticancer activity on leukemia cell line: Design, synthesis, DFT and molecular modelling studies. Carbohydr Res 2020;487:107894.&#13;
11. Ramesh V, Rao BA, Sharma P, Swarna B, Thummuri D, Srinivas K, et al. Synthesis and biological evaluation of new rhodanine analogues bearing 2-chloroquinoline and benzo [h] quinoline scaffolds as anticancer agents. Eur J Med Chem 2014;83:569-80.&#13;
12. Yin LJ, Ahmad Kamar AK, Fung GT, Liang CT, Avupati VR. Review of anticancer potentials and structure-activity relationships (SAR) of rhodanine derivatives. Biomed Pharmacother 2022;145:112406.&#13;
13. Gualtieri M, Bastide L, Villain-Guillot P, MichauxCharachon S, Latouche J, Leonetti JP. In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms. J Antimicrob Chemother 2006;58:778-83.&#13;
14. Harathi N, Reddy SP, Sura M, Daddam JR. Structure prediction, molecular simulations of RmlD from Mycobacterium tuberculosis, and interaction studies of Rhodanine derivatives for anti-tuberculosis activity. J Mol Model 2021;27:75.&#13;
15. Insuasty B, Insuasty A, Tigreros A, Quiroga J, Abonia R, Nogueras M, et al. Synthesis and antifungal evaluation&#13;
of novel dicyanoderivatives of rhodanine. J Heterocycl Chem 2011;48:347-50.&#13;
16. Brand;auml;se S. Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation. London, United Kingdom: Royal Society of Chemistry; 2015.&#13;
17. El-Miligy MM, Hazzaa AA, El-Messmary H, Nassra RA, El-Hawash SA. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study. Bioorg Chem 2017;72:102-15.&#13;
18. Yang N, Ren Z, Zheng J, Feng L, Li D, Gao K, et al. 5-(4-hydroxy-3-dimethoxybenzylidene)-rhodanine (RD-1)-improved mitochondrial function prevents anxiety-and depressive-like states induced by chronic corticosterone injections in mice. Neuropharmacology&#13;
19. Tand;iacute;mea R. Influence of Chemical Compounds and Cellautonomous Immunity on the Replication of Sexually Transmitted Pathogens; 2020.&#13;
20. Dewan M. A Review on Diabetic Neuropathy and Development of Sustained Release Tablet Containing ‘Epalrestat’. Bangladesh: Brac University; 2018.&#13;
21. Privado M, Cuesta V, de la Cruz P, Keshtov ML, Singhal R, Sharmad GD, et al. Efficient polymer solar cells with high open-circuit voltage containing diketopyrrolopyrrole-based non-fullerene acceptor core end-capped with rhodanine units. ACS Appl Mater Interfaces 2017;9:11739-48.&#13;
22. Lee CH, Chiang CL, Liu SJ. Electrospun nanofibrous rhodanine/polymethylmethacrylate membranes for the removal of heavy metal ions. Sep Purif Technol 2013;118:737-43.&#13;
23. Akram D, Elhaty IA, AlNeyadi SS. Synthesis and spectroscopic characterization of rhodanine azo dyes as selective chemosensors for detection of iron (III). Chem Data Collect 2020;28:100456.&#13;
24. Ooyama Y, Harima Y. Molecular designs and syntheses of organic dyes for dye-sensitized solar cells. Eur J Org Chem 2009;2009:2903-34.&#13;
25. Mousavi SM, Zarei M, Hashemi SA, Babapoor A, Amani AM. A conceptual review of rhodanine: Current applications of antiviral drugs, anticancer and antimicrobial activities. Artif Cells Nanomed Biotechnol 2019;47:1132-48.&#13;
26. Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-ene-4- thiazolidinones-an efficient tool in medicinal chemistry. Eur J Med Chem 2017;140:542-94.&#13;
27. Brown FC, Bradsher CK, Morgan EC, Tetenbaum M, Wilder P Jr. Some 3-substituted rhodanines. J Am Chem Soc 1956;78:384-8.&#13;
28. Yarovenko VN, Nikitina AS, Zavarzin IV, Krayushkin MM, Kovalenko LV. A convenient synthesis of N-substituted 2-thioxo-1, 3-thiazolidin-4-ones. Synthesis 2006;8:1246-8.&#13;
29. Radi M, Botta L, Casaluce G, Bernardini M, Botta M. Practical one-pot two-step protocol for the microwaveassisted synthesis of highly functionalized rhodanine derivatives. J Comb Chem 2010;12:200-5.&#13;
30. Nitsche C, Klein CD. Aqueous microwave-assisted onepot synthesis of N-substituted rhodanines. Tetrahedron Lett 2012;53:5197-201.&#13;
31. Liang Y, Tang ML, Huo Z, Zhang C, Sun X. A concise approach to N-substituted rhodanines through a baseassisted one-pot coupling and cyclization process. Molecules 2020;25:1138.&#13;
32. Tissaoui K, Raouafi N, Boujlel K. Electrogenerated base-promoted synthesis of N-benzylic rhodanine and carbamodithioate derivatives. J Sulfur Chem 2010;31:41-8.&#13;
33. Tomaand;scaron;i? T, Maand;scaron;i? LP. Rhodanine as a scaffold in drug discovery: A critical review of its biological activities and mechanisms of target modulation. Expert Opin Drug Discov 2012;7:549-60.&#13;
34. Cozza G, Pinna LA, Moro S. Protein kinase CK2 inhibitors: A patent review. Expert Opin Ther Pat 2012;22:1081-97.&#13;
35. Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007;7:1302-29.&#13;
36. Patel AB, Kumari P. Recent advances in the biological importance of rhodanine derivatives. In: Varala R. Scope of Selective Heterocycles from Organic and Pharmaceutical Perspective. Croatia: IntechOpen; 2016. p. 49-64.&#13;
37. Spicer T, Minond D, Enogieru I, Saldanha S, Allais C, Liu Q, et al. ML302, a novel beta-lactamase (BLA) inhibitor. Probe Reports from the NIH Molecular Libraries Program; 2014.&#13;
38. Orchard MG, Neuss JC, Galley CM, Carr A, Porter DW, Smith P, et al. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg Med Chem Lett 2004;14:3975-8.&#13;
39. Russell AJ, Westwood IM, Crawford MH, Robinson J, Kawamura A, Redfield C, et al. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2.Bioorg Med Chem 2009;17:905-18.&#13;
40. Kumar G, Parasuraman P, Sharma SK, Banerjee T, Karmodiya K, Surolia N, et al. Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. J Med Chem 2007;50:2665-75.</References>